- Market cap
- $184.59M
- 52w range
- $1.70 - $3.72
- Beta
- 0.92
- Sector
- Healthcare
- Data quality
- 75/100
- fair value estimate
- $4.01
- Margin of safety
- +56.6%
- Moat score
- 10/100
- Return on equity
- -30.1%
- Debt / equity
- 0.26
- Analyst target
- $11.33
- Target upside
- +342.7%
- Analysts
- 6
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Valuation
Derived from filed metrics · High confidence (75% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).